pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·1h ago·1 min read
save

Marrow raises $173M for siRNA drug competing with CRISPR therapy for sickle cell

When the FDA approved two gene therapies for sickle cell disease in December 2023, many drugmakers viewed it as the end of the story and shelved their programs for the condition. Yet three years on ...

Nov 17, 2026·read at Endpoints ↗

Romesh Subramanian, Marrow Therapeutics CEO November 17, 2026 07:00 AM EST FinancingCell/Gene Tx Mar­row rais­es $173M for siR­NA drug to com­pete with one-time CRISPR ther­a­py for sick­le cell Ryan Cross Senior Science Correspondent When the FDA ap­proved two gene ther­a­pies for sick­le cell dis­ease in De­cem­ber 2023, many drug­mak­ers viewed it as the end of the sto­ry and … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
93 words · retrieved 5m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1h agoRoche enters the SERD market with FDA approval in late-stage breast cancerEndpoints
  • 14h ago#CTAD26: AriBio’s repurposing of ED drug for Alzheimer’s yields tepid resultsEndpoints
  • 16h agoLilly strikes up to $5.9B cancer deal with Stipple BioEndpoints
  • 17h agoAstraZeneca, Alexion's myasthenia gravis treatment enters crowded marketEndpoints
  • 18h agoHelus Pharma notches successful Phase 3 depression readoutEndpoints